Transcription activator like effector (TALE)-directed piggyBac transposition in human cells

Jesse B. Owens, Damiano Mauro, Ilko Stoytchev, Mital S. Bhakta, Moon Soo Kim, David Segal, Stefan Moisyadi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Insertional therapies have shown great potential for combating genetic disease and safer methods would undoubtedly broaden the variety of possible illness that can be treated. A major challenge that remains is reducing the risk of insertional mutagenesis due to random insertion by both viral and non-viral vectors. Targetable nucleases are capable of inducing double-stranded breaks to enhance homologous recombination for the introduction of transgenes at specific sequences. However, off-target DNA cleavages at unknown sites can lead to mutations that are difficult to detect. Alternatively, the piggyBac transposase is able perform all of the steps required for integration; therefore, cells confirmed to contain a single copy of a targeted transposon, for which its location is known, are likely to be devoid of aberrant genomic modifications. We aimed to retarget transposon insertions by comparing a series of novel hyperactive piggyBac constructs tethered to a custom transcription activator like effector DNA-binding domain designed to bind the first intron of the human CCR5 gene. Multiple targeting strategies were evaluated using combinations of both plasmid-DNA and transposase-protein relocalization to the target sequence. We demonstrated user-defined directed transposition to the CCR5 genomic safe harbor and isolated single-copy clones harboring targeted integrations.

Original languageEnglish (US)
Pages (from-to)9197-9207
Number of pages11
JournalNucleic Acids Research
Volume41
Issue number19
DOIs
StatePublished - Oct 2013

Fingerprint

Transposases
DNA Cleavage
Inborn Genetic Diseases
Insertional Mutagenesis
Homologous Recombination
DNA
Transgenes
Introns
Plasmids
Clone Cells
Mutation
Genes
Proteins
Transcription Activator-Like Effectors
Therapeutics

ASJC Scopus subject areas

  • Genetics

Cite this

Owens, J. B., Mauro, D., Stoytchev, I., Bhakta, M. S., Kim, M. S., Segal, D., & Moisyadi, S. (2013). Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. Nucleic Acids Research, 41(19), 9197-9207. https://doi.org/10.1093/nar/gkt677

Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. / Owens, Jesse B.; Mauro, Damiano; Stoytchev, Ilko; Bhakta, Mital S.; Kim, Moon Soo; Segal, David; Moisyadi, Stefan.

In: Nucleic Acids Research, Vol. 41, No. 19, 10.2013, p. 9197-9207.

Research output: Contribution to journalArticle

Owens, JB, Mauro, D, Stoytchev, I, Bhakta, MS, Kim, MS, Segal, D & Moisyadi, S 2013, 'Transcription activator like effector (TALE)-directed piggyBac transposition in human cells', Nucleic Acids Research, vol. 41, no. 19, pp. 9197-9207. https://doi.org/10.1093/nar/gkt677
Owens, Jesse B. ; Mauro, Damiano ; Stoytchev, Ilko ; Bhakta, Mital S. ; Kim, Moon Soo ; Segal, David ; Moisyadi, Stefan. / Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. In: Nucleic Acids Research. 2013 ; Vol. 41, No. 19. pp. 9197-9207.
@article{892e176efe77477b99af858c98b0025a,
title = "Transcription activator like effector (TALE)-directed piggyBac transposition in human cells",
abstract = "Insertional therapies have shown great potential for combating genetic disease and safer methods would undoubtedly broaden the variety of possible illness that can be treated. A major challenge that remains is reducing the risk of insertional mutagenesis due to random insertion by both viral and non-viral vectors. Targetable nucleases are capable of inducing double-stranded breaks to enhance homologous recombination for the introduction of transgenes at specific sequences. However, off-target DNA cleavages at unknown sites can lead to mutations that are difficult to detect. Alternatively, the piggyBac transposase is able perform all of the steps required for integration; therefore, cells confirmed to contain a single copy of a targeted transposon, for which its location is known, are likely to be devoid of aberrant genomic modifications. We aimed to retarget transposon insertions by comparing a series of novel hyperactive piggyBac constructs tethered to a custom transcription activator like effector DNA-binding domain designed to bind the first intron of the human CCR5 gene. Multiple targeting strategies were evaluated using combinations of both plasmid-DNA and transposase-protein relocalization to the target sequence. We demonstrated user-defined directed transposition to the CCR5 genomic safe harbor and isolated single-copy clones harboring targeted integrations.",
author = "Owens, {Jesse B.} and Damiano Mauro and Ilko Stoytchev and Bhakta, {Mital S.} and Kim, {Moon Soo} and David Segal and Stefan Moisyadi",
year = "2013",
month = "10",
doi = "10.1093/nar/gkt677",
language = "English (US)",
volume = "41",
pages = "9197--9207",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "19",

}

TY - JOUR

T1 - Transcription activator like effector (TALE)-directed piggyBac transposition in human cells

AU - Owens, Jesse B.

AU - Mauro, Damiano

AU - Stoytchev, Ilko

AU - Bhakta, Mital S.

AU - Kim, Moon Soo

AU - Segal, David

AU - Moisyadi, Stefan

PY - 2013/10

Y1 - 2013/10

N2 - Insertional therapies have shown great potential for combating genetic disease and safer methods would undoubtedly broaden the variety of possible illness that can be treated. A major challenge that remains is reducing the risk of insertional mutagenesis due to random insertion by both viral and non-viral vectors. Targetable nucleases are capable of inducing double-stranded breaks to enhance homologous recombination for the introduction of transgenes at specific sequences. However, off-target DNA cleavages at unknown sites can lead to mutations that are difficult to detect. Alternatively, the piggyBac transposase is able perform all of the steps required for integration; therefore, cells confirmed to contain a single copy of a targeted transposon, for which its location is known, are likely to be devoid of aberrant genomic modifications. We aimed to retarget transposon insertions by comparing a series of novel hyperactive piggyBac constructs tethered to a custom transcription activator like effector DNA-binding domain designed to bind the first intron of the human CCR5 gene. Multiple targeting strategies were evaluated using combinations of both plasmid-DNA and transposase-protein relocalization to the target sequence. We demonstrated user-defined directed transposition to the CCR5 genomic safe harbor and isolated single-copy clones harboring targeted integrations.

AB - Insertional therapies have shown great potential for combating genetic disease and safer methods would undoubtedly broaden the variety of possible illness that can be treated. A major challenge that remains is reducing the risk of insertional mutagenesis due to random insertion by both viral and non-viral vectors. Targetable nucleases are capable of inducing double-stranded breaks to enhance homologous recombination for the introduction of transgenes at specific sequences. However, off-target DNA cleavages at unknown sites can lead to mutations that are difficult to detect. Alternatively, the piggyBac transposase is able perform all of the steps required for integration; therefore, cells confirmed to contain a single copy of a targeted transposon, for which its location is known, are likely to be devoid of aberrant genomic modifications. We aimed to retarget transposon insertions by comparing a series of novel hyperactive piggyBac constructs tethered to a custom transcription activator like effector DNA-binding domain designed to bind the first intron of the human CCR5 gene. Multiple targeting strategies were evaluated using combinations of both plasmid-DNA and transposase-protein relocalization to the target sequence. We demonstrated user-defined directed transposition to the CCR5 genomic safe harbor and isolated single-copy clones harboring targeted integrations.

UR - http://www.scopus.com/inward/record.url?scp=84886048819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886048819&partnerID=8YFLogxK

U2 - 10.1093/nar/gkt677

DO - 10.1093/nar/gkt677

M3 - Article

C2 - 23921635

AN - SCOPUS:84886048819

VL - 41

SP - 9197

EP - 9207

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 19

ER -